Altimmune ALT 深 沪
等待开盘 11-11 09:30:00 美东时间
1.94
-0.180
-8.49%
华盛通- 最 高2.13
- 今 开2.12
- 成交量 399.13万股
- 最 低 1.90
- 昨 收 2.12
- 总市值 3.77亿
- 52周最高 6.4399
- 市盈率 静 --
- 换手率 2.05%
- 52周最低 1.90
- 委 比 -39.53%
- 总股本 1.95亿
- 历史最高 237.30
- 量 比 1.16
- 振 幅 10.85%
- 历史最低 1.51
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多iShares Diversified Alternatives收涨1.92%，成交额935.04万美元
11月10日，iShares Diversified Alternatives（ALT）收涨1.92%，报2.12美元，成交额935.04万美元，市值4.12亿...
11-10 07:14
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Altimmune, Inc. will report its third quarter 2026 financial results on November 12, 2026. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call will be webcast live on Altimmune’s Investor Relations website. Participants can register here to receive dial-in numbers and a unique PIN. A replay will be available on the website for up to three months. Altimmune is devel...
11-05 13:00
iShares Diversified Alternatives收跌0.98%，成交额558.6万美元
11月3日，iShares Diversified Alternatives（ALT）收跌0.98%，报2.02美元，成交额558.6万美元，市值3.93亿美元...
11-03 07:13
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Altimmune, Inc. announced that Peter Greenleaf and Alex Howarth will join its board of directors, effective November 2, 2026, as part of a planned transition to align with the company's growth into a late-stage clinical company developing pemvidutide for serious liver diseases. John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the board at the 2027 Annual Meeting. Greenleaf and Howarth bring extensive experien...
10-27 12:00
iShares Diversified Alternatives收跌2.3%，成交额548.42万美元
10月24日，iShares Diversified Alternatives（ALT）收跌2.3%，报2.12美元，成交额548.42万美元，市值4.12亿美...
10-24 06:16
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Altimmune announced new clinical and preclinical data on pemvidutide for liver diseases, to be presented at AASLD’s Liver Meeting 2026. The IMPACT Phase 2b study showed improvements in liver fibrosis and inflammation markers, with favorable gastrointestinal tolerability. Preclinical data demonstrated reduced alcohol intake in a hamster model, supporting further investigation in alcohol-related liver diseases. Oral and poster presentations will hi...
10-19 12:00
iShares Diversified Alternatives收跌6.78%，成交额947.17万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:15
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
The latest update is out from Altimmune ( ($ALT) ). On September 24, 2026, Alti...
09-29 19:29
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
09-23 21:11
